DataMeds AI, Inc MEDS
3.11
(0.39)
(11.14%)
as of 25 Sep
- Market cap
- $10.9M
- P/E
- 0.0×
Follow MEDS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+7 more TTM periods Free account |
(4,010.50%) | 3,545.16% | 1,447.25% | 949.27% | |
| (294.64%) | (230.71%) | (173.68%) | (202.97%) | ||
ROIC |
(143.70%) | (532.81%) | (702.13%) | 0.00% | |
Return on Tangible Assets |
395.66% | 378.86% | 261.96% | 262.67% | |
Average Days of Receivables |
11.78 | 17.79 | 25.91 | 54.61 | |
Free Cash Flow per Share |
(5.07) | (8.27) | (6.56) | (5.69) | |
Free Cash Flow |
(7.55) | (11.74) | (13.73) | (14.66) | |
Capital Expenditures |
(0.36) | (0.88) | (0.81) | (0.92) | |
Piotroski F-Score |
1.00 | 1.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(18.04%) | (97.95%) | (208.62%) | (517.09%) | |
Accounts Receivable Turnover |
47.45 | 9.56 | 5.66 | 3.09 | |
Accounts Payable Turnover |
5.47 | 3.30 | 2.08 | 1.38 | |
Inventory Turnover |
0.00 | 5.34 | 3.67 | 2.90 | |
Average Days of Payables |
121.31 | 143.36 | 208.79 | 301.58 | |
Days of Inventory on Hand |
87.09 | 20.10 | 29.81 | 36.04 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
210.60% | 306.61% | 328.83% | 599.71% | |
Share Based Compensation of Revenue |
162.92% | 234.79% | 202.21% | 357.07% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.09 | 0.11 | 0.17 | 0.16 | |
Depreciation/Fixed assets |
13.00 | 68.95 | 83.54 | 99.10 | |
Capex/Depreciation |
(0.10) | (0.06) | (0.05) | (0.05) | |
Revenue per Share |
22.91 | 16.44 | 6.71 | 3.12 | |
Operating CF per Share |
(4.83) | (7.65) | (6.18) | (5.33) | |
Capex per Share |
(0.24) | (0.62) | (0.39) | (0.36) | |
Capex to Sales |
0.01 | 0.04 | 0.06 | 0.12 | |
Net Profit Margin |
(228.17%) | (433.95%) | (545.72%) | (1,100.29%) |
Columns are period end dates